142 related articles for article (PubMed ID: 22619293)
1. Successful use of omalizumab in an inadequately controlled type 2 diabetic patient with severe insulin allergy.
Cavelti-Weder C; Muggli B; Keller C; Babians-Brunner A; Biason-Lauber A; Donath MY; Schmid-Grendelmeier P
Diabetes Care; 2012 Jun; 35(6):e41. PubMed ID: 22619293
[No Abstract] [Full Text] [Related]
2. Long-term treatment of severe recalcitrant atopic dermatitis with omalizumab, an anti-immuno-globulin E.
Quist SR; Ambach A; Göppner D; Quist J; Franke I; Bonnekoh B; Gollnick HP
Acta Derm Venereol; 2013 Mar; 93(2):206-8. PubMed ID: 23042516
[No Abstract] [Full Text] [Related]
3. Successful treatment of a bullous urticaria with omalizumab.
Ozturk AB; Kocaturk E; Ozturk E
Allergol Int; 2014 Sep; 63(3):495-7. PubMed ID: 24957115
[No Abstract] [Full Text] [Related]
4. Omalizumab (anti-IgE) therapy increases blood glucose levels in severe persistent allergic asthma patients with diabetes mellitus: 18 month follow-up.
Yalcin AD; Gorczynski RM; Cilli A; Strauss L
Clin Lab; 2014; 60(9):1561-4. PubMed ID: 25291953
[TBL] [Abstract][Full Text] [Related]
5. Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors.
MacGlashan DW; Savage JH; Wood RA; Saini SS
J Allergy Clin Immunol; 2012 Nov; 130(5):1130-1135.e5. PubMed ID: 22800400
[TBL] [Abstract][Full Text] [Related]
6. Immunoglobulin E monitoring and reduction of omalizumab therapy in children and adolescents.
Steiss JO; Schmidt A; Nährlich L; Zimmer KP; Rudloff S
Allergy Asthma Proc; 2012; 33(1):77-81. PubMed ID: 22370532
[TBL] [Abstract][Full Text] [Related]
7. Ligelizumab for Chronic Spontaneous Urticaria.
Maurer M; Giménez-Arnau AM; Sussman G; Metz M; Baker DR; Bauer A; Bernstein JA; Brehler R; Chu CY; Chung WH; Danilycheva I; Grattan C; Hébert J; Katelaris C; Makris M; Meshkova R; Savic S; Sinclair R; Sitz K; Staubach P; Wedi B; Löffler J; Barve A; Kobayashi K; Hua E; Severin T; Janocha R
N Engl J Med; 2019 Oct; 381(14):1321-1332. PubMed ID: 31577874
[TBL] [Abstract][Full Text] [Related]
8. Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy.
Nadeau KC; Schneider LC; Hoyte L; Borras I; Umetsu DT
J Allergy Clin Immunol; 2011 Jun; 127(6):1622-4. PubMed ID: 21546071
[No Abstract] [Full Text] [Related]
9. [Disease modification and duration of omalizumab treatment in patients with severe allergic asthma].
Schreiber J; Kopp MV; Korn S; Taube C; Buhl R
Pneumologie; 2014 Mar; 68(3):187-92. PubMed ID: 24477463
[TBL] [Abstract][Full Text] [Related]
10. Omalizumab, an Anti-IgE mAb, receives approval for the treatment of chronic idiopathic/spontaneous urticaria.
Wu KCP; Jabbar-Lopez ZK
J Invest Dermatol; 2015 Jan; 135(1):13-15. PubMed ID: 25501377
[TBL] [Abstract][Full Text] [Related]
11. Complete remission of severe chronic recurrent angioedema of unknown cause with omalizumab.
von Websky A; Reich K; Steinkraus V; Breuer K
J Dtsch Dermatol Ges; 2013 Jul; 11(7):677-8. PubMed ID: 23575040
[No Abstract] [Full Text] [Related]
12. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey.
Deschildre A; Marguet C; Salleron J; Pin I; Rittié JL; Derelle J; Taam RA; Fayon M; Brouard J; Dubus JC; Siret D; Weiss L; Pouessel G; Beghin L; Just J
Eur Respir J; 2013 Nov; 42(5):1224-33. PubMed ID: 23520319
[TBL] [Abstract][Full Text] [Related]
13. Omalizumab. An option in vernal keratoconjunctivitis?
Sánchez J; Cardona R
Allergol Immunopathol (Madr); 2012; 40(5):319-20. PubMed ID: 21975146
[No Abstract] [Full Text] [Related]
14. An algorithm for treating chronic urticaria with omalizumab: dose interval should be individualized.
Uysal P; Eller E; Mortz CG; Bindslev-Jensen C
J Allergy Clin Immunol; 2014 Mar; 133(3):914-5.e2. PubMed ID: 24360324
[No Abstract] [Full Text] [Related]
15. Monitoring omalizumab treatment efficacy in chronic urticaria by the basophil activation test.
Rodríguez-Trabado A; Fernández Pereira LM; Romero-Chala S; García-Trujillo JA; Cámara Hijón C
Allergol Immunopathol (Madr); 2012; 40(6):390-2. PubMed ID: 22178123
[No Abstract] [Full Text] [Related]
16. Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.
Özgür ES; Özge C; Ïlvan A; Naycı SA
J Asthma; 2013 Aug; 50(6):687-94. PubMed ID: 23557459
[TBL] [Abstract][Full Text] [Related]
17. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab.
Gasser P; Tarchevskaya SS; Guntern P; Brigger D; Ruppli R; Zbären N; Kleinboelting S; Heusser C; Jardetzky TS; Eggel A
Nat Commun; 2020 Jan; 11(1):165. PubMed ID: 31913280
[TBL] [Abstract][Full Text] [Related]
18. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
Metz M; Ohanyan T; Church MK; Maurer M
J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603
[TBL] [Abstract][Full Text] [Related]
19. Imported fire ant rush desensitization using omalizumab and a premedication regimen.
Tille KS; Parker AL
Ann Allergy Asthma Immunol; 2014 Nov; 113(5):574-6. PubMed ID: 25216971
[No Abstract] [Full Text] [Related]
20. [Omalizumab therapy in adolescents with severe allergic asthma - results of a post-marketing surveillance].
Klyucheva M; von Berg A; Gappa M; Suerbaum C; Berdel D
Pneumologie; 2013 Apr; 67(4):233-7. PubMed ID: 23576201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
